On October 5, 2018 Genoscience Pharma reported the extension to US of its Phase 1b/2a clinical study with GNS561 in advanced liver cancers (cholangiocarcinoma and hepatocellular carcinoma) (Press release, GenoScience, OCT 5, 2018, View Source [SID1234530226]). In October 2017, GNS561 received an IND for an international clinical trial involving up to 50 patients with liver cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Opened Clinical Centers

Memorial Sloan Kettering Cancer Center (MSKCC) – New York, USA – enrolled its first liver cancer patient in the ongoing Phase 1b/2a clinical trial to evaluate the safety and efficacy of GNS561. MSKCC is one of the five clinical centers participating to patients’ recruitment in our study, with Jules Bordet Institute (Brussels, Belgium), Saint-Joseph Hospital, AP-HP (Paris, France), Croix Rousse Hospital (Lyon, France), Hospitalo-Universitary Center of Grenoble (Grenoble, France).

MSKCC

Memorial Sloan Kettering Cancer Center — the world’s oldest and largest private cancer center — has devoted more than 130 years to exceptional patient care, innovative research, and outstanding educational programs.